AI enabled precision diagnostics for heart muscle diseases with hypertrophy

人工智能实现了心肌肥厚疾病的精确诊断

• 批准号: 10072606
• 金额: $ 93.56万
• 依托单位: MYCARDIUM AI LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10072606
• 关键词: AI; enabled; precision; diagnostics; heart

**Cardiomyopathy** is a disease that affects the heart muscle and can cause heart failure and sudden death. The most common genetic type of this disease is called hypertrophic cardiomyopathy, which thickens the heart. In the last few years, the first of new drugs and gene therapies have been developed to treat this disease more precisely. These are real breakthroughs - for the first time promising not just disease control, but cure, and potentially even prevention.However, to treat this disease effectively , doctors need to be able to diagnose it with greater certainty. Currently, doctors use complex scans to diagnose patients, but these scans don't take into account differences in sex, ethnicity, and body size, which can result in misdiagnosis and mistreatment.Researchers in London have developed artificial intelligence technology that can measure heart scans more accurately than human experts. By using this technology, they have created new personalized diagnostic criteria that take into account differences in sex, ethnicity, and body size. They have also developed blood tests to diagnose and predict the risk of hypertrophic cardiomyopathy, distinguish diseases that resemble it and to help doctors choose the right treatment.A UK company called Mycardium AI Ltd, founded by disease and AI experts from UCL, is using this technology to transform heart disease patient care. Currently focusing only on one sort of scan, MRI, they have already helped thousands of patients and are working with drug companies to develop new treatments.In a partnership with UCL, Imperial, and LYVA labs, Mycardium AI aims to apply their personalized diagnostic criteria to patients worldwide. This will be done using not just MRI, but also ultrasound (echo scans) and new highly precise blood tests. By doing so, they hope to improve the lives of tens of thousands of patients by providing better, earlier treatment that targets their specific needs. This will also streamline care and make society healthier, happier, and wealthier. They plan to deliver their technology through multiple channels to healthcare providers worldwide, helping to usher in a new era of precision diagnostics for cardiology.

**心肌病**是一种影响心肌的疾病，可能导致心力衰竭和猝死。这种疾病最常见的遗传类型是肥厚型心肌病，它使心脏增厚。在过去的几年里，第一批新药和基因疗法已经被开发出来，以更准确地治疗这种疾病。这些都是真正的突破--第一次不仅承诺疾病控制，而且承诺治愈，甚至可能预防。然而，为了有效地治疗这种疾病，医生需要能够更确定地诊断出它。目前，医生使用复杂的扫描来诊断患者，但这些扫描没有考虑到性别、种族和体型的差异，这可能会导致误诊和虐待。伦敦的研究人员开发出了人工智能技术，可以比人类专家更准确地测量心脏扫描。通过使用这项技术，他们创造了新的个性化诊断标准，考虑到了性别、种族和体型的差异。他们还开发了血液测试来诊断和预测肥厚型心肌病的风险，区分与其相似的疾病，并帮助医生选择正确的治疗方法。由伦敦大学学院的疾病和人工智能专家创立的一家名为Mycardium AI Ltd的英国公司正在使用这项技术来改变心脏病患者的护理。目前只专注于一种扫描-MRI，他们已经帮助了数千名患者，并正在与制药公司合作开发新的治疗方法。在与UCL、Imperial和LYVA实验室的合作中，Mycardium AI的目标是将他们的个性化诊断标准应用于世界各地的患者。这将不仅使用核磁共振，而且还将使用超声波(回声扫描)和新的高精度血液测试。通过这样做，他们希望通过提供针对他们特定需求的更好、更早的治疗来改善数万名患者的生活。这也将简化护理，使社会更健康、更幸福、更富裕。他们计划通过多种渠道将他们的技术提供给世界各地的医疗保健提供者，帮助开创心脏病精确诊断的新时代。